Tag: Hexokinase-2 bound to mitochondria: cancer’s stygian link to the “Warburg Effect” and a pivotal target for effective therapy
Hexokinase-2 bound to mitochondria: cancer’s stygian link to the “Warburg Effect” and a pivotal target for effective therapy
- Filipe
- 0
The commonest metabolic hallmark of malignant tumors, i.e., the “Warburg impact” is their propensity to metabolize glucose to lactic acid at a excessive charge even within the presence of oxygen. The pivotal participant on this frequent most cancers phenotype is mitochondrial-bound hexokinase [Bustamante E, Pedersen PL. High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. Proc Natl Acad Sci USA 1977;74(9):3735-9;
Bustamante E, Morris HP, Pedersen PL. Energy metabolism of tumor cells. Requirement for a form of hexokinase with a propensity for mitochondrial binding. J Biol Chem 1981;256(16):8699-704]. Now, in clinics worldwide this outstanding phenotype types the idea of one of the crucial widespread detection techniques for most cancers, i.e., positron emission tomography (PET).
Considerably, HK-2 is the main sure hexokinase isoform expressed in cancers that exhibit a “Warburg impact”. This consists of most cancers that metastasize and kill their human host. By stationing itself on the outer mitochondrial membrane, HK-2 additionally helps immortalize most cancers cells, escapes product inhibition and features preferential entry to newly synthesized ATP for phosphorylating glucose.
The resultant acidity possible wards off an immune response whereas getting ready surrounding tissues for invasion. With the re-emergence and acceptance of each the “Warburg impact” as a outstanding phenotype of most medical cancers, and “metabolic concentrating on” as a rational therapeutic technique, quite a few laboratories are specializing in metabolite entry or exit steps.
Read More
One exceptional success story [Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, et al. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 2004;324(1):269-75] is using the small molecule 3-bromopyruvate (3-BP) that selectively enters and destroys the cells of huge tumors in animals by concentrating on each HK-2 and the mitochondrial ATP synthasome.
read more